Kary Eldred Biography and Net Worth

Director of Galectin Therapeutics

Kary Eldred is a director and Chief Investment Officer for the Living Stones Foundation since July 2015 and has been an active private equity investor for many years. In these capacities, he serves and has served on a number of corporate boards of companies with potential for and driving toward initial public offerings and is currently serving as a board member in Buy It Installed (since 2017), Babywise and Wise King Media (since 2015). Kary Eldred also served on the board and audit committee of GCT Semiconductor. From January 2011 through October 2014, Mr. Eldred was CEO & Chairman of Altadona, S.A. a software integration company based in Europe and prior to that was a principal in Parakletos Ventures, an institutional venture capital firm with several investments in companies that went on to be acquired or become publicly listed on different exchanges around the world including the NASDAQ, KOSDAQ and the GEM market. Mr. Eldred has an Executive MBA from IE Business School and a BA in Foreign Service from Baylor University.

What is Kary Eldred's net worth?: The estimated net worth of Kary Eldred is at least $285.72 thousand as of February 6th, 2026. Mr. Eldred owns 65,682 shares of Galectin Therapeutics stock worth more than $285,717 as of July 1st. This net worth estimate does not reflect any other assets that Mr. Eldred may own. Learn More about Kary Eldred's net worth.
How do I contact Kary Eldred?: The corporate mailing address for Mr. Eldred and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Kary Eldred's contact information.
Has Kary Eldred been buying or selling shares of Galectin Therapeutics?: Kary Eldred has not been actively trading shares of Galectin Therapeutics during the past quarter. Most recently, on Friday, February 6th, Kary Eldred bought 300 shares of Galectin Therapeutics stock. The stock was acquired at an average cost of $2.70 per share, with a total value of $810.00. Following the completion of the transaction, the director now directly owns 65,682 shares of the company's stock, valued at $177,341.40. Learn More on Kary Eldred's trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Jack Callicutt (Chief Financial Officer), Kary Eldred (Director), Kevin Freeman (Director), Joel Lewis (Chief Executive Officer (CEO) and President), Elissa Schwartz (Director), Harold Shlevin (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 3 times. They purchased a total of 2,000 shares worth more than $6,341.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 944,585 shares worth more than $5,050,478.51. The most recent insider tranaction occured on June, 29th when Director Harold H Shlevin sold 22,268 shares worth more than $112,230.72. Insiders at Galectin Therapeutics own 52.6% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 6/29/2026.

Kary Eldred Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/6/2026	Buy	300	$2.70	$810.00	65,682
12/23/2025	Buy	700	$3.73	$2,611.00	65,382
7/21/2025	Buy	1,000	$2.92	$2,920.00	64,682
10/23/2024	Buy	500	$2.60	$1,300.00	50,213
1/16/2024	Buy	500	$1.79	$895.00	49,313
7/19/2023	Buy	1,598	$1.79	$2,860.42	48,813
2/21/2023	Buy	1,000	$1.59	$1,590.00	47,215
1/25/2023	Buy	1,300	$1.11	$1,443.00	46,215
9/25/2018	Buy	2,000	$6.10	$12,200.00	41,382

Kary Eldred Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $4.40

$4.28

$4.64

50 Day Range

MA: $2.65

$2.08

$4.97

2 Week Range

Now: $4.40

$2.03

$7.13

Volume

278,709 shs

Average Volume

459,155 shs

Market Capitalization

$289.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47